General Information of Drug (ID: DMDG8Q3)

Drug Name
Varlitinib Drug Info
Synonyms
VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
Indication
Disease Entry ICD 11 Status REF
Metastatic biliary tract neoplasms 2C14-2C17 Phase 2/3 [1]
Breast cancer 2C60-2C65 Phase 1/2 [2]
Cross-matching ID
PubChem CID
42642648
CAS Number
CAS 845272-21-1
TTD Drug ID
DMDG8Q3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [4]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [5]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [6]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [7]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [8]
Margetuximab DMKEY6S HER2-positive breast cancer 2C60-2C65 Approved [9]
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [10]
Tucatinib DMBESUA HER2-positive breast cancer 2C60-2C65 Approved [11]
Pertuzumab DMHJV0X Adrenal gland neoplasm Approved [12]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [14]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [4]
Gefitinib DM15F0X Colon adenocarcinoma Approved [15]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [16]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [17]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [18]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [6]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [19]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [18]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Modulator [3]
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Modulator [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7645).
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
6 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
7 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
8 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
12 Clinical pipeline report, company report or official report of Roche (2009).
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
15 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
16 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
17 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
19 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.